PhD Barbara Breznik

PhD Barbara Breznik
no.: 36319 source: ARIS

researcher – active in research organisation
Edit
Research activity

Code Science Field Subfield
1.03.00  Natural sciences and mathematics  Biology   
3.04.00  Medical sciences  Oncology   
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
536.49
A''
57.91
A'
143.38
A1/2
277.66
CI10
1,117
CImax
300
h10
17
A1
1.76
A3
0.53
Data for the last 5 years (citations for the last 10 years) on November 11, 2025; Data for score A3 calculation refer to period 2020-2024 (2020, 2021, 2022, 2023, 2024)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 48  1,222  1,031  21.48 
Scopus 47  1,315  1,108  23.57 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (100%, RD:100%)  National Institute of Biology  Department of Genetic Toxicology and Cancer Biology 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. BI-TR/25-27-003  Assessing the combinatorial effects of Arginine Methyltransferase (PRMT) inhibitors and radiotherapy on glioblastoma organoids   9/1/2025 - 8/31/2027  PhD Barbara Breznik   219 
2. N3-0394  Organoid Dynamics for Combating Glioblastoma Treatment Resistance   1/1/2025 - 12/31/2026  PhD Barbara Breznik   307 
3. NC-25002  Targeting glioblastoma cells in tumour microenvironment combining irradiation with selective metalloprotease inhibitors   1/1/2025 - 12/31/2026  PhD Barbara Breznik   307 
4. J3-4504  Uncovering the glioblastoma microenvironment to enhance the therapy   10/1/2022 - 9/30/2025  PhD Metka Novak   2,035 
5. L3-3176  The Role and Potential Application of Immunomodulatory Mesenchymal Stem Cells in COVID- 19 Disease   10/1/2021 - 9/30/2024  PhD Janja Zupan   3,692 
6. BI-US/22-24-007  The role of MAGE proteins in glioblastoma stem cells and therapy resistance: can knowledge of stem cell biology help us treat therapy-resistant brain tumors?   7/1/2022 - 6/30/2024  PhD Barbara Breznik   219 
7. NC-0023  Innovative Probes and Inhibition of Metalloproteases for Targeting Glioblastoma Stem Cells in Tumour Microenvironment   2/1/2022 - 1/31/2024  PhD Barbara Breznik   1,259 
8. J3-2516  Cystatin f as a mediator of immunosuppression in glioblastoma microenvironment   9/1/2020 - 8/31/2023  PhD Milica Perišić Nanut   2,911 
9. J3-2526  Unravelling glioma stem cell niches for novel therapeutic targets in glioblastoma patients   9/1/2020 - 8/31/2023  PhD Cornelis J.F. van Noorden   2,576 
10. Z3-1870  The impact of mesenchymal stem cells on glioblastoma therapeutic resistance   7/1/2019 - 2/28/2022  PhD Barbara Breznik   219 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0245  Ecotoxicology, toxicogenomics and carcinogenesis   1/1/2019 - 12/31/2027 PhD Bojana Žegura   3,134 
2. P1-0245  Ecotoxicology, toxicogenomics and carcinogenesis   1/1/2015 - 12/31/2018 PhD Tamara Lah Turnšek   3,490 
3. P1-0245  Ekotoksiologija, toksikološka genomika in karcinogeneza (Slovene)   1/1/2009 - 12/31/2014 PhD Tamara Lah Turnšek   3,535 
We were not given permission by the researcher to publish data.
Confirmation required
Views history
Favourite